QQQ   418.51 (-1.16%)
AAPL   164.99 (-1.23%)
MSFT   401.25 (-0.75%)
META   487.67 (-2.82%)
GOOGL   154.54 (-0.94%)
AMZN   176.26 (-1.65%)
TSLA   150.03 (+0.07%)
NVDA   817.75 (-3.42%)
AMD   149.59 (-3.54%)
NIO   3.86 (-3.50%)
BABA   68.89 (+0.01%)
T   16.29 (-0.24%)
F   12.09 (+0.25%)
MU   107.19 (-4.23%)
GE   150.22 (-1.78%)
CGC   7.68 (-1.92%)
DIS   111.75 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.77 (+1.50%)
PYPL   62.04 (-0.10%)
XOM   120.08 (+1.32%)
QQQ   418.51 (-1.16%)
AAPL   164.99 (-1.23%)
MSFT   401.25 (-0.75%)
META   487.67 (-2.82%)
GOOGL   154.54 (-0.94%)
AMZN   176.26 (-1.65%)
TSLA   150.03 (+0.07%)
NVDA   817.75 (-3.42%)
AMD   149.59 (-3.54%)
NIO   3.86 (-3.50%)
BABA   68.89 (+0.01%)
T   16.29 (-0.24%)
F   12.09 (+0.25%)
MU   107.19 (-4.23%)
GE   150.22 (-1.78%)
CGC   7.68 (-1.92%)
DIS   111.75 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.77 (+1.50%)
PYPL   62.04 (-0.10%)
XOM   120.08 (+1.32%)
QQQ   418.51 (-1.16%)
AAPL   164.99 (-1.23%)
MSFT   401.25 (-0.75%)
META   487.67 (-2.82%)
GOOGL   154.54 (-0.94%)
AMZN   176.26 (-1.65%)
TSLA   150.03 (+0.07%)
NVDA   817.75 (-3.42%)
AMD   149.59 (-3.54%)
NIO   3.86 (-3.50%)
BABA   68.89 (+0.01%)
T   16.29 (-0.24%)
F   12.09 (+0.25%)
MU   107.19 (-4.23%)
GE   150.22 (-1.78%)
CGC   7.68 (-1.92%)
DIS   111.75 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.77 (+1.50%)
PYPL   62.04 (-0.10%)
XOM   120.08 (+1.32%)
QQQ   418.51 (-1.16%)
AAPL   164.99 (-1.23%)
MSFT   401.25 (-0.75%)
META   487.67 (-2.82%)
GOOGL   154.54 (-0.94%)
AMZN   176.26 (-1.65%)
TSLA   150.03 (+0.07%)
NVDA   817.75 (-3.42%)
AMD   149.59 (-3.54%)
NIO   3.86 (-3.50%)
BABA   68.89 (+0.01%)
T   16.29 (-0.24%)
F   12.09 (+0.25%)
MU   107.19 (-4.23%)
GE   150.22 (-1.78%)
CGC   7.68 (-1.92%)
DIS   111.75 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.77 (+1.50%)
PYPL   62.04 (-0.10%)
XOM   120.08 (+1.32%)
Free Trial

Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Compare

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CorMedix Inc. stock logo
CRMD
CorMedix
$5.37
-0.9%		$4.01
$2.57
▼
$7.00
$294.33M1.86539,614 shs1.05 million shs
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
$23.18
+5.3%		$23.02
$4.55
▼
$27.72
$693.78M1.41235,250 shs127,634 shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CorMedix Inc. stock logo
CRMD
CorMedix
-0.37%-15.18%+41.51%+66.26%+12.33%
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
+2.13%-1.52%-5.66%+19.61%+232.88%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CorMedix Inc. stock logo
CRMD
CorMedix
1.4182 of 5 stars		3.50.00.00.03.01.70.6
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
2.2721 of 5 stars		3.53.00.00.02.41.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CorMedix Inc. stock logo
CRMD
CorMedix
3.00
Buy$13.00142.09% Upside
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
3.00
Buy$57.25146.98% Upside

Current Analyst Ratings

Latest CRMD, SLN, and BVXP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/9/2024
CorMedix Inc. stock logo
CRMD
CorMedix
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingMarket Outperform ➝ Market Outperform$19.00
4/9/2024
CorMedix Inc. stock logo
CRMD
CorMedix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy ➝ Buy$10.00
3/15/2024
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy ➝ Buy$75.00
3/14/2024
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Price TargetBuy ➝ Buy$26.00 ➝ $42.00
3/14/2024
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Price TargetOverweight ➝ Overweight$29.00 ➝ $45.00
3/13/2024
CorMedix Inc. stock logo
CRMD
CorMedix
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.00
2/22/2024
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy ➝ Buy$75.00
1/31/2024
CorMedix Inc. stock logo
CRMD
CorMedix
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Price TargetBuy ➝ Buy$18.00 ➝ $14.00
1/31/2024
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageOutperform$67.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CorMedix Inc. stock logo
CRMD
CorMedix
$60K4,905.50N/AN/A$1.28 per share4.20
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
$31.55M21.99N/AN/A$0.71 per share32.65

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CorMedix Inc. stock logo
CRMD
CorMedix
-$46.34M-$0.92N/AN/AN/AN/A-72.31%-63.97%5/20/2024 (Estimated)
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
-$53.82M-$1.46N/AN/AN/A-171.41%-262.17%-45.62%5/21/2024 (Estimated)

Latest CRMD, SLN, and BVXP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/13/2024Q4 2023
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
-$0.25-$0.47-$0.22-$0.47$11.46 million$2.61 million
3/12/2024Q4 2023
CorMedix Inc. stock logo
CRMD
CorMedix
-$0.21-$0.26-$0.05-$0.26N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CorMedix Inc. stock logo
CRMD
CorMedix
N/AN/AN/AN/AN/A
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CorMedix Inc. stock logo
CRMD
CorMedix
N/A
6.97
6.78
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
0.01
4.56
4.56

Ownership

Institutional Ownership

CompanyInstitutional Ownership
CorMedix Inc. stock logo
CRMD
CorMedix
34.18%
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
98.73%

Insider Ownership

CompanyInsider Ownership
CorMedix Inc. stock logo
CRMD
CorMedix
3.60%
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
2.95%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
CorMedix Inc. stock logo
CRMD
CorMedix
8254.81 million52.84 millionOptionable
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
10929.93 million29.05 millionNot Optionable

CRMD, SLN, and BVXP Headlines

SourceHeadline
Radio Silence says Ready or Not 2 is happening and “it’s an absolute f*cking banger of a sequel”Radio Silence says Ready or Not 2 is happening and “it’s an absolute f*cking banger of a sequel”
flickeringmyth.com - April 16 at 6:30 PM
Silence Therapeutics (NASDAQ:SLN) Trading Up 3.2%Silence Therapeutics (NASDAQ:SLN) Trading Up 3.2%
marketbeat.com - April 16 at 2:02 PM
Nia Archives Unveils Debut Album Silence Is LoudNia Archives Unveils Debut Album 'Silence Is Loud'
trenchtrenchtrench.com - April 13 at 2:08 AM
A youths call to action on this Day of NO SilenceA youth's call to action on this Day of NO Silence
yahoo.com - April 13 at 2:08 AM
Silence Therapeutics plc (NASDAQ:SLN) Short Interest UpdateSilence Therapeutics plc (NASDAQ:SLN) Short Interest Update
marketbeat.com - April 12 at 10:21 PM
Acts of Silence in LiteratureActs of Silence in Literature
today.duke.edu - April 12 at 9:51 AM
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
zacks.com - April 12 at 9:26 AM
Silence Therapeutics (NASDAQ:SLN) Sees Strong Trading VolumeSilence Therapeutics (NASDAQ:SLN) Sees Strong Trading Volume
marketbeat.com - April 11 at 2:49 PM
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 20243 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
investorplace.com - April 11 at 12:24 PM
Silence Therapeutics (NASDAQ:SLN) Stock Price Down 4.5%Silence Therapeutics (NASDAQ:SLN) Stock Price Down 4.5%
marketbeat.com - April 9 at 2:46 PM
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
businesswire.com - April 8 at 11:48 AM
The Lady of Silence: The Mataviejitas Murders Streaming: Watch & Stream Online via NetflixThe Lady of Silence: The Mataviejitas Murders Streaming: Watch & Stream Online via Netflix
yahoo.com - April 1 at 10:11 AM
7 Biotech Stocks Ready to Ride the Sectors Resurgence7 Biotech Stocks Ready to Ride the Sector's Resurgence
investorplace.com - March 18 at 8:01 PM
Analysts Are Upgrading Silence Therapeutics plc (NASDAQ:SLN) After Its Latest ResultsAnalysts Are Upgrading Silence Therapeutics plc (NASDAQ:SLN) After Its Latest Results
finance.yahoo.com - March 16 at 10:20 AM
Silence Therapeutics plc (SLN) Q4 2023 Earnings Call TranscriptSilence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 15 at 5:54 PM
YouTube Music preparing ‘Trim Silence’ option for podcastsYouTube Music preparing ‘Trim Silence’ option for podcasts
9to5google.com - March 15 at 12:53 PM
Silence Therapeutics plc (NASDAQ:SLN) Q4 2023 Earnings Call TranscriptSilence Therapeutics plc (NASDAQ:SLN) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 15 at 12:53 PM
Local authors Break the Silence with book anthology to share the stories of survivorsLocal authors 'Break the Silence' with book anthology to share the stories of survivors
yahoo.com - March 13 at 1:14 PM
SingTel looking to sell significant Optus stake to Brookfield - sourceSingTel looking to sell significant Optus stake to Brookfield - source
sg.finance.yahoo.com - March 13 at 1:14 PM
Mallinckrodt, Silence collab to go quiet, but a phase 2 cardiovascular win speaks loudly for the biotechMallinckrodt, Silence collab to go quiet, but a phase 2 cardiovascular win speaks loudly for the biotech
fiercebiotech.com - March 13 at 1:14 PM
Silence Therapeutics plc 2023 Q4 - Results - Earnings Call PresentationSilence Therapeutics plc 2023 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 13 at 7:52 AM
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsSilence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
businesswire.com - March 13 at 7:05 AM
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
businesswire.com - March 13 at 7:00 AM
Silence Therapeutics earnings: heres what Wall Street expectsSilence Therapeutics earnings: here's what Wall Street expects
markets.businessinsider.com - March 12 at 10:34 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CorMedix logo

CorMedix

NASDAQ:CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Silence Therapeutics logo

Silence Therapeutics

NASDAQ:SLN
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.